Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy


Original post, click here
Primary Outcome Measures:
Secondary Outcome Measures:

  • Percent change of low-density lipoprotein cholesterol (LDL-C) [ Time Frame: Baseline and 4 weeks ]

    Assess the 1-month efficacy of bempedoic acid 180 mg/day vs placebo in the reduction of LDL-C in patients on PCSK9i therapy

  • Percent change of apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), and high-sensitivity C-reactive protein (hs-CRP) [ Time Frame: Baseline, 4 weeks, and 8 weeks ]

    Evaluate the effect of bempedoic acid 180 mg/day vs placebo on ApoB, non-HDL-C, TC, and hs-CRP after 1 and 2 months in patients on PCSK9i therapy

  • Number of adverse events (AE) and serious adverse events (SAE) [ Time Frame: Baseline through 8 weeks ]

    Evaluate the safety and tolerability of bempedoic acid 180 mg/day compared to placebo in patients on PCSK9i therapy